National AIDS Memorial to Launch 50-State AIDS Memorial Quilt Virtual Exhibition in Conjunction with World AIDS Day
October 09, 2020 14:49 ET
|
National AIDS Memorial
San Francisco, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The National AIDS Memorial is announcing a virtual exhibition of the AIDS Memorial Quilt (the Quilt) that will feature more than 10,000 Quilt panels...
Vivent Health Announces Partnership with National AIDS Memorial
June 23, 2020 11:45 ET
|
National AIDS Memorial
Milwaukee, June 23, 2020 (GLOBE NEWSWIRE) -- Vivent Health announced today a long-term partnership with the National AIDS Memorial, a nonprofit devoted to the remembrance of people lost to AIDS that...
National AIDS Memorial Awards $50,000 in Scholarships to Young Leaders Committed to Helping End the HIV/AIDS Epidemic
October 24, 2019 12:17 ET
|
National AIDS Memorial
San Francisco, Oct. 24, 2019 (GLOBE NEWSWIRE) -- The Pedro Zamora Young Leaders Scholarship, a program of the National AIDS Memorial, has awarded ten undergraduate students a total of $50,000 in...
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017
May 31, 2017 09:14 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable,...
CORRECTING and REPLACING: Immune Therapeutics, Inc.
May 22, 2017 09:24 ET
|
Immune Therapeutics, Inc.
In a release issued under the same headline earlier today by Immune Therapeutics, Inc. (OTCQB:IMUN), the headline has been corrected to read "Immune Therapeutics Announces NAFDAC Approval...
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
May 22, 2017 08:42 ET
|
Immune Therapeutics, Inc.
Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture...
Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio
March 30, 2017 09:45 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics Clears Critical Certification Milestone
February 02, 2017 09:40 ET
|
Immune Therapeutics, Inc.
Immune Therapeutics Receives Approval for Lodonal™ from theDominican Republic’s Ministry of Health and Social Assistance ORLANDO, Fla., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics,...
UPDATE -- Immune Therapeutics Issues Special Letter to Shareholders
January 30, 2017 10:48 ET
|
Immune Therapeutics, Inc.
Company Expects to Report Initial Revenues in First Half of 2017 and Achieve Profitability by Year-End Company to Host Investor Conference Call to Discuss Positive Developments ORLANDO, Fla.,...
Immune Therapeutics Issues Special Letter to Shareholders
January 30, 2017 08:40 ET
|
Immune Therapeutics, Inc.
Company Expects to Report Initial Revenues in First Half of 2017 and Achieve Profitability by Year-End Company to Host Investor Conference Call to Discuss Positive Developments ORLANDO, Fla.,...